Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics

Abstract

Delineating the contributions of specific cell signalling cascades to the development and maintenance of tumours has greatly informed our understanding of tumorigenesis and has advanced the modern era of targeted cancer therapy. It has been revealed that one of the key pathways regulating cell growth, the phosphatidylinositol 3-kinase/mechanistic target of rapamycin (PI3K/mTOR) signalling axis, is commonly dysregulated in cancer. With a specific, well-tolerated inhibitor of mTOR available, the impact of inhibiting this pathway at the level of mTOR has been tested clinically. This review highlights some of the promising results seen with mTOR inhibitors in the clinic and assesses some of the challenges that remain in predicting patient outcome following mTOR-targeted therapy.

Keywords

Mechanistic target of rapamycin / cancer / rapamycin / rapalog / clinical trial / resistance

References

[1] Saxton RA.mTOR signaling in growth, metabolism, and disease..Cell2017;168:960-76 PMCID:PMC5394987

[2] Loewith R,Wullschleger S,Crespo JL.Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control..Mol Cell2002;10:457-68

[3] Sancak Y,Peterson TR,Kang SA.PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase..Mol Cell2007;25:903-15

[4] Peterson TR,Thoreen CC,Kang SA.Deptor is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival..Cell2009;137:873-86 PMCID:PMC2758791

[5] Ramirez-Rangel I,Vazquez-Macias A,Reyes-Cruz G.Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57..Mol Cell Biol2011;31:1657-71 PMCID:PMC3126338

[6] Kaizuka T,Oshiro N,Yonezawa K.Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly..J Biol Chem2010;285:20109-16 PMCID:PMC2888423

[7] Saci A,Carpenter CL.Rac1 regulates the activity of mTORC1 and mTORC2 and controlscellular size..Mol Cell2011;42:50-61 PMCID:PMC3750737

[8] Gaubitz C,Kusmider B.TORC2 structure and function. Trends Biochem..Sci2016;41:532-45

[9] Inoki K,Zhu T,Guan KL.TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling..Nat Cell Biol2002;4:648-57

[10] Manning BD,Logsdon MN,Cantley LC.Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway..Mol Cell2002;10:151-62

[11] Potter CJ,Xu T.Akt regulates growth by directly phosphorylating Tsc2..Nat Cell Biol2002;4:658-65

[12] Puertollano R.mTOR and lysosome regulation..F1000Prime Rep2014;6:52 PMCID:PMC4108950

[13] Tee AR.The target of rapamycin and mechanisms of cell growth..Int J Mol Sci2018;19:E880 PMCID:PMC5877741

[14] Kim J.mTOR as a central hub of nutrient signalling and cell growth..Nat Cell Biol2019;21:63-71

[15] Nojima H,Eguchi S,Hidayat S.The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif..J Biol Chem2003;278:15461-4

[16] Gingras AC,O’Leary MA,Hay N.4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway..Genes Dev1998;12:502-13 PMCID:PMC316523

[17] Dodd KM,Shen MH,Tee AR.mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3..Oncogene2015;34:2239-50 PMCID:PMC4172452

[18] Düvel K,Menon S,Lipovsky AI.Activation of a metabolic gene regulatory network downstream of mTOR complex 1..Mol Cell2010;39:171-83 PMCID:PMC2946786

[19] Csibi A,Li C,Choo AY.The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4..Cell2013;153:840-54 PMCID:PMC3684628

[20] Porstmann T,Griffiths B,Wu M.SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth..Cell Metab2008;8:224-36 PMCID:PMC2593919

[21] Li S,Goldstein JL.Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis..PNAS2010;107:3441-6 PMCID:PMC2840492

[22] Dunlop EA.The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis..Biochem Soc Trans2013;41:939-43

[23] Vezina C,Sehgal SN.Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle..J Antibiot (Tokyo)1975;28:721-6

[24] Asleh R,Kremers WK,Boilson BA.Long-term sirolimus for primary immunosuppression in heart transplant recipients..J Am Coll Cardiol2018;71:636-50

[25] Viana SD,Alves R.Therapeutic use of mTOR inhibitors in renal diseases: advances, drawbacks, and challenges..Oxid Med Cell Longev2018;2018:3693625 PMCID:PMC6231362

[26] Aylett CH,Imseng S,Hall MN.Architecture of human mTOR complex 1..Science2016;351:48-52

[27] Yuan H.Structural insights of mTOR complex 1..Cell Res2016;26:267-8 PMCID:PMC4783463

[28] Kolos JM,Bauder M.FKBP ligands - where we are and where to go?.Fron Pharm2018;9:1425 PMCID:PMC6290070

[29] Kirchner GI,Manns MP.Clinical pharmacokinetics of everolimus..Clin Pharmacokinet2004;43:83-95

[30] Crowe A,Duerr L,Lemaire M.Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats..Drug Metab Dispos1999;27:627-32

[31] Choo AY,Kim SG,Blenis J.Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation..Proc Natl Acad Sci U S A2008;105:17414-9 PMCID:PMC2582304

[32] Cassell A,Lee J,Wang L.Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models..Neoplasia2012;14:1005-14 PMCID:PMC3514742

[33] Lou HZ,Pan HM,Sun P.The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells..Biochem Biophys Res Commun2014;450:973-8

[34] Li C,Chen MB,Liu F.The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent..Cancer Biol Ther2015;16:34-42 PMCID:PMC4623257

[35] Basu B,Puglisi M,Ong M.First-in-human pharmacokinetic and pharmacodynamics study of the dual mTORC1/2 inhibitor AZD2014..Clin Cancer Res2015;21:3412-9 PMCID:PMC4512239

[36] Powles T,Din O,Boleti E.A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer..Eur Urol2016;69:450-6

[37] Álvarez-Garcia V,Wise HM.Mechanisms of PTEN loss in cancer: It’s all about diversity..Semin Cancer Biol2019;Epub ahead of print [PMID: 30738865 DOI: 10.1016/j.semcancer.2019.02.001]

[38] Ma L,Erdjument-Bromage H,Pandolfi PP.Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis..Cell2005;121:179-93

[39] Carrière A,Julien LA,Bonneil E.Oncogenic MAPK signalling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation..Curr Biol2008;18:1269-77

[40] Hobbs GA,Rossman KL.RAS isoforms and mutations in cancer at a glance..J Cell Sci2016;129:1287-92 PMCID:PMC4869631

[41] Holderfield M,McCormick F.Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond..Nat Rev Cancer2014;14:455-67 PMCID:PMC4250230

[42] Guo Y,Zhang J,Gray NS.TSC1 involvement in bladder cancer: diverse effects and therapeutic implications..J Pathol2013;230:17-27

[43] Yuan F,Ji J,Zhou C.KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors..Int J Biol Sci2014;10:957-65 PMCID:PMC4159686

[44] Huynh H,Chan SL,Ong R.Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus..Mol Cancer Ther2015;14:1224-35

[45] Zhang Y,Kucherlapati M,Liu Y.A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations..Cancer Cell2017;31:820-32 PMCID:PMC5502825

[46] Grabiner BC,Birsoy K,Shen K.A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity..Cancer Discov2014;4:554-63 PMCID:PMC4012430

[47] Bissler JJ,Young LR,Chuck G.Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis..N Engl J Med2008;358:140-51 PMCID:PMC3398441

[48] Davies DM,Johnson SR,Cox JA.Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial..Clin Cancer Res2011;17:4071-81

[49] Cabrera López C,Catalá V,Mateu S.Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis..Nefrologia2011;31:292-8

[50] Krueger DA,Holland K,Tudor C.Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis..N Engl J Med2010;363:1801-11

[51] Dabora SL,Ashwal S,DiMario FJ Jr.Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease..PLoS One2011;6:e23379 PMCID:PMC3167813

[52] Franz DN,Sparagana S,Frost M.Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial..Lancet2013;381:125-32

[53] Saffari A,Wiemer-Kriel A,Kreuzaler P.Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study..Orphanet J Rare Dis2019;14:96 PMCID:PMC6500021

[54] Pantuck AJ,Klatte T,Leppert JT.Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy..Cancer2007;109:2257-67

[55] Motzer RJ,Oudard S,Porta C.Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial..Lancet2008;372:449-56

[56] Motzer RJ,Oudard S,Porta C.Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors..Cancer2010;116:4256-65

[57] Stein A,Escudier B,Stergiopoulos SG.Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial..Eur Urol2013;64:994-1002

[58] Escudier B,Bracarda S,Szczylik C.Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis..Eur J Cancer2016;69:226-35

[59] Missiaglia E,Barbi S,Falconi M.Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway..J Clin Oncol2010;28:245-55 PMCID:PMC4288616

[60] Yao JC,Baudin E,Rougier P.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial..J Clin Oncol2010;28:69-76 PMCID:PMC4295034

[61] Yao JC,Ito T,Wolin EM.Everolimus for advanced pancreatic neuroendocrine tumors..N Engl J Med2011;364:514-23 PMCID:PMC4208619

[62] Yao JC,Singh S,Carnaghi C.Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study..Lancet2016;387:968-77 PMCID:PMC6063317

[63] Fazio N,Delle Fave G,Wolin E.Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis..Cancer Sci2018;109:174-81 PMCID:PMC5765303

[64] Lau DK,Yeung YH,Mooi J.Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study..Br J Cancer2018;118:966-71 PMCID:PMC5931084

[65] Demetri GD,Ray-Coquard I,Staddon AP.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy..J Clin Oncol2013;31:2485-92

[66] Doi T,Boku N,Nishina T.Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer..J Clin Oncol2010;28:1904-10

[67] Ohtsu A,Bai YX,Chung HC.Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study..J Clin Oncol2013;31:3935-43 PMCID:PMC5950503

[68] O’Donnell A,Burris HA,Papadimitrakopoulou V.Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors..J Clin Oncol2008;26:1588-95

[69] Reungwetwattana T,Mandrekar SJ,Rowland KM.Brief report: a phase II “window-of-opportunity” frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study..J Thorac Oncol2012;7:919-22 PMCID:PMC5740874

[70] Besse B,Bennouna J,Blais N.Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer..Ann Oncol2014;25:409-15

[71] Ng K,Hwang J,Sharma S.Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens..Clin Cancer Res2013;19:3987-95 PMCID:PMC3725595

[72] Tabernero J,Calvo E,Judson I.Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors..J Clin Oncol2008;26:1603-10

[73] Spindler KL,Pallisgaard N,Havelund BM.Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma..Acta Oncol2013;52:963-70

[74] Armstrong AJ,Halabi S,Bitting RL.A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer..Clin Genitourin Cancer2013;11:397-406

[75] Templeton AJ,Cathomas R,Bärtschi D.Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)..Eur Urol2013;64:150-8

[76] O’Reilly KE,She QB,Mills GB.mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt..Cancer Res2006;66:1500-8 PMCID:PMC3193604

[77] Carracedo A,Teruya-Feldstein J,Salmena L.Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer..J Clin Invest2008;118:3065-74 PMCID:PMC2518073

[78] Yu Y,Poulogiannis G,Ma XM.Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signalling..Science2011;332:1322-6 PMCID:PMC3195509

[79] Hsu PP,Rameseder J,Ottina KA.The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signalling..Science2011;332:1317-22 PMCID:PMC3177140

[80] Kim YC.mTOR: a pharmacologic target for autophagy regulation..J Clin Invest2015;125:25-32 PMCID:PMC4382265

[81] Roux PP,Vu H,Cohen MS.RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation..J Biol Chem2007;282:14056-64 PMCID:PMC3618456

[82] Sato T,Guo L,Tamanoi F.Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer..Oncogene2010;29:2746-52 PMCID:PMC2953941

[83] The Cancer Genome Atlas Research NetworkComprehensive molecular characterization of clear cell renal cell carcinoma..Nature2013;499:43-9 PMCID:PMC3771322

[84] Wagle N,van Allen EM,Taylor-Weiner A.Response and acquired resistance to everolimus in anaplastic thyroid cancer..N Engl J Med2014;371:1426-33 PMCID:PMC4564868

[85] Tan J,Li Z,Lim YC.B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer..Cancer Cell2010;18:459-71

[86] Gerlinger M,Horswell S,Larkin J.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing..N Engl J Med2012;366:883-92 PMCID:PMC4878653

[87] El-Chemaly S,Goldberg HJ,Haughey M.Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase i clinical trial..Chest2017;151:1302-10 PMCID:PMC6026235

[88] Haas NB,Stein M,Wilks M.Autophagy inhibition to augment mTOR inhibition: a phase i/ii trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma..Clin Cancer Res2019;25:2080-7

[89] Chi MS,Huang SC,Ko HL.Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients..Oncotarget2015;6:29808-17 PMCID:PMC4745764

[90] Schenone S,Musumeci F,Botta M.ATP-competitive inhibitors of mTOR: an update..Curr Medicin Chem2011;18:2995-3014

[91] Fazio N,Baudin E,Hubner RA.A phase ii study of bez235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours..Anticancer Res2016;36:713-9 PMCID:PMC5076549

[92] Rodon J,Krop IE,Guerrero-Zotano A.Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer..Cancer Chemother Pharmacol2018;82:285-98 PMCID:PMC6286256

[93] Britten CD,Millham R,Borzillo G.Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer..Invest New Drugs2014;32:510-7

[94] Bendell JC,Hyman DM,Pant S.A first-in-human phase 1 study of LY3023414, an oral PI3K/mTOR dual inhibitor, in patients with advanced cancer..Clin Cancer Res2018;24:3253-62

[95] Roberts PJ,Darr DB,Pfefferle AD.Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models..Clin Cancer Res2012;18:5290-303 PMCID:PMC3715399

[96] Tolcher AW,Papadopoulos KP,Patnaik A.A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors..Ann Oncol2015;26:58-64

[97] Liu X,Mita M,Hong DS.Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response..Oncologist2014;19:426-8 PMCID:PMC3983812

[98] Kasner MT,Jeschke GR,Filicko-O’Hara J.Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition..Invest New Drugs2018;36:657-66 PMCID:PMC6060002

[99] Burnett AK,Knapper S,Sweeney M.Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial..Haematologica2018;103:1654-61 PMCID:PMC6165825

[100] Schuetzea SM,Chugh R,Lucas DR.Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma..Eur J Cancer2012;48:1347-53

[101] Wood A,Adra N,Damayanti N.Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma..Invest New Drugs2019;Epub ahead of print [DOI: 10.1007/s10637-019-00864-7]

[102] Tew WP,Walker JL,Bonebrake AJ.Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study..Gynecol Oncol2018;151:257-263 PMCID:PMC6350932

[103] Sherman WH.Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer..JOP2009;10:393-5

[104] Lee JS,Blanchard S,Yin HH.Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer..Breast Cancer Res2019;21:119 PMCID:PMC6839083

[105] Shi Y,Ye Y,Han L.Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway..Cancer Biol Med2018;15:314-21 PMCID:PMC6121052

[106] Parachoniak CA,Gaffney B,Spritz D.Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant..Cold Spring Harb Mol Case Stud2017;3:a000778 PMCID:PMC5593157

[107] Iyer G,Milowsky MI,Scott SN.Genome sequencing identifies a basis for everolimus sensitivity..Science2012;338:221 PMCID:PMC3633467

[108] Yi Z,Liu B,Li L.Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study..BMC Cancer2019;19:442 PMCID:PMC6515626

[109] Bellmunt J,Jacobus S,Polacek L.Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma..Br J Cancer2018;119:707-12 PMCID:PMC6173710

[110] Sharma S,Matrana MR,Chiorean EG.A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss..J Clin Oncol2019;37:

[111] Kwiatkowski DJ,Fay AP,Thorner AR.Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma..Clin Cancer Res2016;22:2445-52 PMCID:PMC4976069

[112] Lynch TJ,Sordella R,Okimoto RA.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib..N Engl J Med2004;350:2129-39

[113] Juengel E,Makarevic J,Tsaur I.Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib..J Cell Mol Med2015;19:430-41 PMCID:PMC4407590

[114] Motzer RJ,Glen H,Molina A.Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial..Lancet Oncol2015;16:1473-82

[115] Matsubara N,Nakano K,Ikezawa H.Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: a phase 1 study..Int J Urol2018;25:922-8

[116] Hutson TE,Esteban E,Lim HY.Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma..J Clin Oncol2014;32:760-7 PMCID:PMC5569683

[117] Zarrabi K,Wu S.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy..J Hematol Oncol2017;10:38 PMCID:PMC5288948

[118] Paplomata E,Santa-Maria CA,Gogineni K.Use of everolimus and trastuzumab in addition to endocrine therapy in hormone-refractory metastatic breast cancer..Clin Breast Cancer2019;19:188-96

[119] Bachelot T,Cropet C,Ferrero JM.Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study..J Clin Oncol2012;30:2718-24

[120] Baselga J,Piccart M,Rugo HS.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer..N Engl J Med2012;366:520-9 PMCID:PMC5705195

[121] Kornblum N,Manola J,Ramaswamy B.Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102..J Clin Oncol2018;36:1556-63

[122] Shimoi T,Shien T,Kato H.Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)..Open Access J Clin Trials2018;10:13-8

[123] Schmid P,Harper-Wynne C,Dubey S.Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial..JAMA Oncol2019;Epub head of print [DOI: 10.1001/jamaoncol.2019.2526]

[124] Yoon DH,Park YS,Lee C.Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum..Br J Cancer2012;106:1039-44 PMCID:PMC3304416

[125] Buzzoni R,Bajetta E,Platania M.Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study..Ann Oncol2014;25:1597-603

[126] Brose MS,Yarchoan M,Harlacker K.A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone..J Clin Oncol2015;33:6072

[127] Hanna GJ,Chau NG,Barletta JA.Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase ii study..Clin Cancer Res2018;24:1546-53

[128] Wolpin BM,Zhu AX,Enzinger PC.Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer..Oncologist2013;18:377-8 PMCID:PMC3639523

[129] Lombard-Bohas C,Hobday T,Wolin E.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial..Pancreas2015;44:181-9 PMCID:PMC4327560

[130] Rodrik-Outmezguine VS,Yao Z,McWhirter C.Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor..Nature2016;534:272-6 PMCID:PMC4902179

[131] Fan Q,Wong RA,Novotny CJ.A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma..Cancer Cell2017;31:424-35 PMCID:PMC5386178